AstraZeneca PLC (AZN)vsOmniAb Inc. (OABI)
AZN
AstraZeneca PLC
$163.78
-1.18%
HEALTHCARE · Cap: $252.33B
OABI
OmniAb Inc.
$4.35
-2.90%
HEALTHCARE · Cap: $629.54M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 159470% more annual revenue ($61.37B vs $38.46M). AZN leads profitability with a 17.0% profit margin vs -115.1%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
OABI
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$163.78
$32.32 discount
Intrinsic value data unavailable for OABI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 244.2% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : OABI
The strongest argument for OABI centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 244.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while OABI is a hypergrowth play — different risk/reward profiles.
OABI carries more volatility with a beta of 1.42 — expect wider price swings.
OABI is growing revenue faster at 244.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 32/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?